Next-Gen Therapies: Unlocking the Potential of Bispecific ADCs Infographic

Next-Gen Therapies: Unlocking the Potential of Bispecific ADCs

As the competition in both traditional ADC and bispecific sectors intensifies, bispecific ADCs (BsADCs) are emerging as a key differentiator for developers looking to stand out. In 2023 alone, a record 25 BsADCs were publicly disclosed and 4 entered clinical trials, marking an incredible 50% annual growth rate over the past six years!

Our infographic reveals how these next-generation therapies are overcoming the limitations of existing modalities. Download your copy to leverage Beacon’s powerful data and seize the immense opportunity this field has to offer.

Bispecific ADCs Infographic

Covered in this Infographic:

Drug Status and Trial Phases: Understand the current development stages of BsADCs and their progression through various trial phases.
Developer Locations: Visualize the geographic distribution of developers working on these drugs.
Benefits of BsADCs: Explore the advantages of utilizing this cutting-edge therapy.
Top Targets: Identify the key targets in this field and the strategies being used for target selection.

Download Infographic

You May Also Be Interested In…

Bispecific Landscape Review

Access Review

SITC 2024: Bispecific Post-Conference Report

Access Report

ASCO 2024: Bispecific Highlights

Access Infographic

View All

What is Beacon?

Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.

Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements

Find out more